EBEmma Beltrán

Emma Beltrán

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Emma Beltrán has a total of 470 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: multicentre study of 80 patients

    by José Luis Martín-Varillas, Lara Sanchez-Bilbao, Vanesa Calvo-Río, Alfredo Adán, Inés Hernanz, Adela Gallego-Flores, Emma Beltran-Catalan, Sonia Castro-Oreiro, Patricia Fanlo, Alvaro Garcia Martos, et al.

    Objectives To evaluate effectiveness and safety of certolizumab pegol (CZP) in uveitis due to immune-mediated inflammatory diseases (IMID). Methods Multicentre study of CZP-treated patients with IMID uveitis refractory to conventional immunosuppressant. Effectiveness was assessed through the following ocular parameters: best-corrected visual acuity, anterior chamber cells, vitritis, macular thickness and retinal vasculitis. These variables were compared between the baseline, and first week, first, third, sixth months, first and second year. Results We studied 80 (33 men/47 women) patients (111 affected eyes) with a mean age of 41.6±11.7 years. The IMID included were: spondyloarthritis (n=43), Behçet’s disease (n=10), psoriatic arthritis (n=8), Crohn’s disease (n=4), sarcoidosis (n=2), juvenile idiopathic arthritis (n=1), reactive arthritis (n=1), rheumatoid arthritis (n=1), relapsing polychondritis (n=1), Conclusions CZP seems to be effective and safe in uveitis related to different IMID, even in patients refractory to previous biological drugs.


  • Open Access

    Nitrogen flow analysis in Spain: Perspectives to increase sustainability

    by Álvaro Mayor, Emma Beltran, J.L. Cortina, C. Valderrama


  • Open Access

    POS1350 UVEITIS DUE TO IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATED WITH CERTOLIZUMAB PEGOL. MULTICENTER STUDY OF 80 PATIENTS.

    by J. L. Martín-Varillas, L. Sanchez-Bilbao, V. Calvo-Río, A. Adan, I. Hernanz Rodriguez, E. Beltrán, S. Castro, P. Fanlo Mateo, A. García Martos, I. Torre-Salaberri, et al.

    Background Adalimumab remains the only biologic approved by the EMA and FDA for the treatment of non-infectious uveitis [1-6]. The reports on efficacy of other anti-TNF drugs such as Certolizumab Pegol (CZP) are scarce. Objectives to determine the efficacy and safety of CZP in refractory uveitis secondary to Immune-mediated Inflammatory Diseases (IMIDs). Methods national multicenter study of 80 patients with uveitis due to IMID refractory to glucocorticoids and conventional immunosuppressants treated with CZP. Efficacy was assessed with the following ocular parameters: best corrected visual acuity (BCVA), anterior chamber cells, vitritis, macular thickness and presence of retinal vasculitis. The efficacy of CZP was compared between the baseline visit, 1st week, 1st and 6th month, and 1st year. Statistical analysis was performed with IBM SPSS Statistics v.23. Results we studied 80 patients/111 affected eyes (33 men/47 women) with a mean age of 41.6±11.7 years. The IMIDs included were: spondyloarthritis (n=43), Behçet’s disease (10), psoriatic arthritis (8), Crohn’s disease (4), sarcoidosis (2), JIA (1), reactive arthritis (1), rheumatoid arthritis (1), relapsing polychondritis (1), TINU (1), pars planitis (1), Birdshot (1) and idiopathic uveitis (6). Anterior was the most frequent uveitis pattern (n=61). In 20 patients, besides the presence of refractory uveitis, desire of pregnancy was the reason for CZP initiation. Prior to CZP, patients had received: methotrexate (n=38), sulfasalazine (28), azathioprine (14), cyclosporine (10), leflunomide (3), mycophenolate mofetil (4), and cyclophosphamide (1). Previous biologic therapy was administered in 52 patients (63%), with a median [IQR] of 2 [1-3] drugs per patient. The most used biologic was adalimumab (n=48), followed by infliximab (32), golimumab (15), tocilizumab (5), etanercept (7), rituximab (1), anakinra (1) and secukinumab (1). CZP was administered as monotherapy in 39 patients. After 24 [12-36] months of follow-up, all parameters analyzed showed a rapid and maintained improvement (Table 1). A decrease in the mean number of uveitis flares was observed before and after CZP, (2.6±2.3 vs. 0.6±0.4, pConclusion CZP seems to be effective and safe in the control of uveitis associated to different IMIDs. References [1]Jaffe GJ, et al. N Engl J Med 2016;375:932-43. doi: 10.1056/NEJMoa1509852. [2]Nguyen QD, et al. Lancet 2016;388:1183-92. doi: 10.1016/S0140-6736(16)31339-3. [3]Martín-Varillas JL, et al. Ophthalmology 2018; 125:1444-1451 doi: 10.1016/j.ophtha.2018.02.020 [4]Martín-Varillas JL, et al. J Rheumatol. 2021;48:741-750. doi: 10.3899/jrheum.200300 [5]Atienza-Mateo B. Arthritis Rheumatol. 2019;71:2081-2089. doi: 10.1002/art.41026. [6]Vegas-Revenga N et al Am J Ophthalmol. 2019;200:85-94. doi: 10.1016/j.ajo.2018.12.019 Disclosure of Interests None declared

  • Open Access

    SAT0264 LONG TERM FOLLOW-UP AND OPTIMIZATION OF INFLIXIMAB IN REFRACTORY UVEITIS DUE TO BEHÇET'S DISEASE. MULTICENTER STUDY OF 103 CAUCASIAN PATIENTS

    by J. L. Martín-Varillas, B. Atienza-Mateo, V. Calvo-Río, E. Beltrán, A. Adan, E. Aurrecoechea, S. Castañeda, M. A. González-Gay, J. L. Hernández, R. Blanco

    Background: Biologic therapy has improved prognosis of Behçet Disease (BD) uveitis (1-5). Although infliximab (IFX) is approved in Japan, most data in Caucasian patients comes from small series. No data on optimization has been published Objectives: In a large series of Caucasian patients with refractory uveitis of BD, we assess: a) long-term efficacy and safety; b) IFX optimization when ocular remission was achieved Methods: Multicenter study of IFX-treated patients with BD uveitis refractory to conventional immunosuppressants.103 patients were treated with IFX as 1st biologic as follows: 3-5 mg/kg i.v. at 0, 2, 6 and every 4-8 weeks. The main outcomes were anterior chamber cells, vitritis, retinal vasculitis, macular thickness, visual acuity, and glucocorticoids sparing effect; analysed at baseline, 1st week, 1st and 6th months and 1st and 2nd years. After remission, IFX optimization was performed Results: In whole series (n=103), main outcomes showed a rapid and maintained improvement, reaching remission in 78 patients after a mean IFX duration of 31.5 months. Severe side-effects were observed in 9 patients. Comparative study between optimized and non-optimized groups showed: a) no differences in clinical baseline characteristics; b) similar maintained improvement in most ocular outcomes; c) lower severe adverse events and d) lower IFX cost in optimized group (4826.52 vs 9854.13 euros/patient/year) (Table) Conclusion: IFX seems effective and safe in Caucasian patients with refractory BD uveitis. IFX optimization is effective, safe, and cost-effective References: [1]Martín-Varillas JL. Ophthalmology 2018;125:1444-1451. [2]Atienza-Mateo B: Arthritis Rheumatol. 2019;71:2081-2089 [3]Santos-Gómez M. Clin Exp Rheumatol. 2016;34 (6 Suppl 102): S34-S40 [4]Urruticoechea-Arana A. Rheumatol Int. 2019;39:47-58. [5]Atienza-Mateo B. Rheumatology (Oxford). 2018 1;57:856-864 Disclosure of Interests: José Luis Martín-Varillas Grant/research support from: AbbVie, Pfizer, Janssen and Celgene, Speakers bureau: Pfizer and Lilly, Belén Atienza-Mateo: None declared, Vanesa Calvo-Río Grant/research support from: MSD and Roche, Speakers bureau: AbbVie, Lilly, Celgene, Grünenthal, UCB Pharma, Emma Beltrán: None declared, Alfredo Adan: None declared, Elena Aurrecoechea: None declared, Santos Castañeda: None declared, Miguel A González-Gay Grant/research support from: Pfizer, Abbvie, MSD, Speakers bureau: Pfizer, Abbvie, MSD, J. Luis Hernández: None declared, Ricardo Blanco Grant/research support from: AbbVie, MSD, and Roche, Speakers bureau: AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, and MSD


  • Magnetic resonance imaging assessment in patients with axial spondyloarthritis: development of checklists for use in clinical practice

    by Raquel Almodóvar, Ángel Bueno, Enrique Batlle, Emma Beltrán-Catalán, Daniel Bernabeu, Carmen Castro Copete, Angela Cepero, Concha Crespo, Fernando Díez, Cristina Fernández-Carballido, et al.

    The objective of our study was to standardize magnetic resonance imaging (MRI) assessment of spine and sacroiliac joints in patients with axial spondyloarthritis (axSpA) and/or inflammatory spinal pain, by creating checklists and templates based on the opinions of rheumatologists and radiologists. A scientific committee developed a series of questionnaires with multiple items regarding MRI in patients with axial inflammatory pain and/or axSpA. Then an expert panel of rheumatologists and radiologists rated all items in a 9-point Likert scale. Finally, the scientific committee and the expert panel met to create the definitive documents. Several definitive checklists and templates were generated for rheumatologist-requested MRI and for radiologist-requested MRI reports of sacroiliac joint and spinal examinations. A technical requirement protocol was also agreed on. Our results could be useful in increasing understanding between rheumatologists and radiologists regarding MRI in axSpA diagnosis and follow-up.


  • THU0566 Adalimumab Optimization in Behcet's Syndrome Refractory Uveitis Once Obtained Remission

    by C. Fernández Díaz, R. Blanco, V. Calvo-Río, J. Loricera, J. Sanchez-Bursόn, N. Ortego, J.L. García-Serrano, M. Cordero-Coma, J. Vazquez, E. Beltran, et al.

    Background In non-infectious no anterior uveitis, adalimumab (ADA) is the only biologic that has shown efficacy in phase III randomized, double blind studies, such as VISUAL I and VISUAL II. (Brezin AP et al Arthritis Rheumatol 2015;67 (suppl 10): 2038 & Nguyen QD et al Arthritis Rheumatol 2015; 67 (suppl 10): 1388). After a 80 mg loading dose, maintenance dose is the standard for other indications, 40 mg/sc/2 weeks. Objectives Our objective is to test a series of Behcet's síndrome uveítis, and proving if once remission was obtained, it was posible to “optimize” the maintenance dose. Methods Multicenter study of 174 patients with Behcet's síndrome refractory uveitis. All of them had insufficient response or intolerance to conventional treatment with corticosteroids and at least 1 systemic immunosuppressive drug. 71 patients started treatment with ADA and once remission was achieved, it was optimized in 23 of them. The degree of ocular inflammation was assessed by “the Standardization of Uveitis Nomenclature (SUN) Working Group” (Am J Ophthalmol 2005; 140: 509–516), and macular thickness by optical coherence tomography (OCT). A comparison was made between the first visit before initializing ADA at standard dose, the start of the optimization of the drug, and the final visit. The results are expressed as mean ± 1 SD for variables with a normal distribution, and as median [IQR 25–75] (range) when it is not normal. Comparison of continuous variables was performed using the Wilcoxon test. Results 23 patients/42 affected eyes (15 men/8 women) who had a dose optimization were studied, the median age was 37.2 ± 13.4 years (range 10–62). HLA-B51 was positive in 60.8%. Prior to ADA, and as systemic treatment besides oral steroids, they had received intravenous methylprednisolone bolus (n=7), cyclosporin A (CyA) (n=20), methotrexate (MTX) (n=11) and azathioprine (AZA) (n=11). ADA monotherapy was used in 5 cases and also in combination with immunosuppressants: CyA (n=12), MTX (n=4) and AZA (n=2). The average remission before optimization of the dose was 15.3 ± 9 months. In 23 patients the interval dose of adalimumab was progressively increased to 3 weeks (n=6), 4 weeks (n=13), 5 weeks (n=1), 6 weeks (n=1) and 8 weeks (n=2). Only 2 patients had to return to the standard dose of ADA due to serious outbreak after optimizing the drug, reaching again remission of uveitis. It was also posible to suspend ADA in 4 patients after 35.2 ± 9.3 months in remission, not presenting a new outbreak after a mean of 20 ± 6.9 months following the suspension. There were not serious side effects during a mean follow-up of 34.7 ± 13.3 months after starting ADA. Conclusions Optimizing ADA therapy, once remission is achieved, seems feasible in Behcet's síndrome uveítis refractory to systemic treatment. Disclosure of Interest None declared

  • FRI0485 Comparative Study on Adalimumab vs Infliximab for Treatment of Uveitic Cystoid Macular Edema Due To Behcet's Disease. Multicentre Study of 34 Patients

    by E. Beltrán-Catalán, V. Calvo-Rio, R. Blanco-Alonso, C. Fernandez, P. Rodriguez, J.M. Herreras, M. Cordero, M. Mesquida, A. Adan, M.V. Hernandez, et al.

    Objectives Cystic macular edema (CME) is the most serious complication of uveitis and the most common cause of blindness. Our objective was to compare the efficacy and safety of adalimumab (ADA) vs infliximab (IFX) as the first biological drug in uveitic cystoid macular edema (CME) due to Behçet's disease (BD) during 1 year follow-up. Methods In a multicentre study of 175 patients with BD and uveitis refractory to conventional therapy, 34 patients had CME, defined by (OCT >300μ) at baseline. IFX (3–5 mg/kg 0,2, and 6 weeks and then every 4–8 weeks) was used in 12 cases and ADA (40 mg/2 weeks) in 22 cases. The main objective was the absence of CME. Secondary objectives: improvement in visual acuity (VA) (increased AV >20% in at least one of two eyes), inactive anterior chamber inflammation, vitritis, retinitis and retinal vasculitis. A bivariate analysis was performed to compare the response to biological therapy (ADA and IFX). Results We studied 34 patients (63 affected eyes). No statistically significant baseline differences were observed between both groups (IFX vs ADA) sex (men/women 4/6 vs 11/11; p=0.35), mean age (37.3±10.1 vs 41.5±8.3; p=0.2) HLAB51 positive (70% vs 80.9%; p=0.5), duration of uveitis before anti TNF alpha treatment [median (IQR]; 36 [10–82] vs 33 months [15.5 to 83]; p=0.8), VA (0.4 ± 0.33 vs 0.46±0.29; p=0.44); retinal vasculitis (75% vs 77%; p=0.87); retinitis (46% vs 30%; p=0.2); macular thickening (140.9±410.13 vs 409.46±138.55; p=0.98); combined treatment (58.33% vs 59.1%; p=0.96). We found differences in the presence of cells in the anterior chamber (Median [IQR]; 1 [0–1.2] vs 1 [0–3]; p=0.02) and vitritis (median [IQR], 1 [0–2] vs. 3 [0.5 -3]; p=0.002). Regarding the main objective, the improvement of CME is higher in patients treated with ADA during first month of treatment maintained at a year, although the difference is not statistically significant (table). With IFX we observed an improvement during the first month of treatment in vitritis, that became inactive, in the disappearance of the anterior chamber cells, and in retinitis and vasculitis that also became inactive. In no case statistically significant differences are reached. When adjusting for duration of illness, age and sex these differences remain. After a year of treatment all patients with retinitis and vasculitis in its baseline improve (ADA and IFX). Conclusions Our study suggests that ADA and IFX don't show statistically significant differences in treatment of CME due to refractory uveitis in BD after 1 year follow-up. Disclosure of Interest None declared

  • Open Access

    Brief Report: IRF4 Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross‐Disease Meta‐Analysis of Genome‐Wide Association Studies

    by Elena López‐Isac, Jose‐Ezequiel Martín, Shervin Assassi, Carmen P. Simeón, Patricia Carreira, Norberto Ortego‐Centeno, Mayka Freire, Emma Beltrán, Javier Narváez, Juan J. Alegre‐Sancho, et al.

    Objective: Systemic sclerosis (SSc) and rheumatoid arthritis (RA) are autoimmune diseases that have similar clinical and immunologic characteristics. To date, several shared SSc–RA genetic loci have been identified independently. The aim of the current study was to systematically search for new common SSc–RA loci through an interdisease meta–genome‐wide association (meta‐GWAS) strategy.Methods: The study was designed as a meta‐analysis combining GWAS data sets of patients with SSc and patients with RA, using a strategy that allowed identification of loci with both same‐direction and opposite‐direction allelic effects. The top single‐nucleotide polymorphisms were followed up in independent SSc and RA case–control cohorts. This allowed an increase in the sample size to a total of 8,830 patients with SSc, 16,870 patients with RA, and 43,393 healthy controls.Results: This cross‐disease meta‐analysis of the GWAS data sets identified several loci with nominal association signals (P < 5 × 10−6) that also showed evidence of association in the disease‐specific GWAS scans. These loci included several genomic regions not previously reported as shared loci, as well as several risk factors that were previously found to be associated with both diseases. Follow‐up analyses of the putatively new SSc–RA loci identified IRF4 as a shared risk factor for these 2 diseases (Pcombined = 3.29 × 10−12). Analysis of the biologic relevance of the known SSc–RA shared loci identified the type I interferon and interleukin‐12 signaling pathways as the main common etiologic factors.Conclusion: This study identified a novel shared locus, IRF4, for the risk of SSc and RA, and highlighted the usefulness of a cross‐disease GWAS meta‐analysis strategy in the identification of common risk loci.


  • Open Access

    Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study

    by Maurizio Cutolo, Ariane L. Herrick, Oliver Distler, Mike O. Becker, Emma Beltran, Patrick Carpentier, Clodoveo Ferri, Murat Inanç, Panayiotis Vlachoyiannopoulos, Harbajan Chadha‐Boreham, et al.

    Objective: To identify nailfold videocapillaroscopic features and other clinical risk factors for new digital ulcers (DUs) during a 6‐month period in patients with systemic sclerosis (SSc).Methods: In this multicenter, prospective, observational cohort study, the videoCAPillaroscopy (CAP) study, we evaluated 623 patients with SSc from 59 centers (14 countries). Patients were stratified into 2 groups: a DU history group and a no DU history group. At enrollment, patients underwent detailed nailfold videocapillaroscopic evaluation and assessment of demographic characteristics, DU status, and clinical and SSc characteristics. Risk factors for developing new DUs were assessed using univariable and multivariable logistic regression (MLR) analyses.Results: Of the 468 patients in the DU history group (mean ± SD age 54.0 ± 13.7 years), 79.5% were female, 59.8% had limited cutaneous SSc, and 22% developed a new DU during follow‐up. The strongest risk factors for new DUs identified by MLR in the DU history group included the mean number of capillaries per millimeter in the middle finger of the dominant hand, the number of DUs (categorized as 0, 1, 2, or ≥3), and the presence of critical digital ischemia. The receiver operating characteristic (ROC) of the area under the curve (AUC) of the final MLR model was 0.738 (95% confidence interval [95% CI] 0.681–0.795). Internal validation through bootstrap generated a ROC AUC of 0.633 (95% CI 0.510–0.756).Conclusion: This international prospective study, which included detailed nailfold videocapillaroscopic evaluation and extensive clinical characterization of patients with SSc, identified the mean number of capillaries per millimeter in the middle finger of the dominant hand, the number of DUs at enrollment, and the presence of critical digital ischemia at enrollment as risk factors for the development of new DUs.


  • Open Access

    Sponyloarthritis features forecasting the presence of HLA-B27 or sacroiliitis on magnetic resonance imaging in patients with suspected axial spondyloarthritis: results from a cross-sectional study in the ESPeranza Cohort

    by Victoria Navarro-Compán, Eugenio de Miguel, Désirée van der Heijde, Robert Landewé, Raquel Almodóvar, Carlos Montilla, Emma Beltrán, Pedro Zarco

    Chronic back pain (CBP) is frequently the presenting symptom in patients with suspected axial spondyloarthritis (axSpA). Presence of sacroiliitis on magnetic-resonance-imaging (MRI) or HLA-B27 adds to diagnostic certainty. However, these costly tests cannot be applied in all patients with CBP. This study aims to investigate which SpA features increase the likelihood of a positive HLA-B27 or positive MRI of the sacroiliac-joints (MRI-SI) in patients with suspected axSpA. Data from 665 patients with CBP within the ESPeranza Programme were analysed. Diagnostic utility measures (LR+, LR−) for a positive MRI-SI or HLA-B27 were calculated for various definitions of inflammatory back pain (IBP), their separate items and for other SpA features. Pretest probabilityies of a positive result was 41 % for MRI-SI and 40 % for HLA-B27. For a positive MRI-SI result the most useful IBP characteristic was alternating buttock pain (LR + =2.6). Among the IBP-criteria, fulfillment of the ‘ASAS criteria’ (LR + =2.1) was most contributory. Interestingly, the addition of alternating buttock pain to the Calin/ASAS-IBP criteria (LR + =6.0 and 5.5, respectively) or the addition of awakening at second half of night to the Calin-IBP criteria (LR + =5.5) increased the pre-test probability of MRI-sacroiliitis from 41 % to 79–80 %. Dactylitis (LR + =4.1) and inflammatory bowel disease (IBD) (LR + =6.4) increased this probability to 73 % and 81 %, respectively. To forecast HLA-B27 positivity, awakening at the second half of the night, fulfillment of the ASAS-IBP definition and uveitis were the most useful, but only marginally predictive (LR + = 1.3, 1,6 and 2.6, respectively). If patients with suspected axial SpA have either 1) IBP according to Calin/ASAS definition plus alternating buttock pain, or 2) IBP according to Calin definition plus awakening at night, or 3) dactylitis or 4) IBD, the probability of finding a positive MRI-SI increases significantly.